Parkinson's disease is one of the most common neurological disorders that primarily affects people over 60 years of age. What triggers the disease is unknown and this may be one of the reasons why there is no effective treatment yet. Studying changes in gene expression in one of the most affected parts of the brain (the striatum) will lead to the establishment of new targets for symptomatic and protective treatments. For that we will use a high-sensitive technology that has been developed in recent years, called "single-cell sequencing", that allows to measure differences in gene expression of every gene and in every cell. We will be able to detect the main transcriptomic differences in every cell population of parkinsonian mouse models, in the striatum, with the resolution of single cell, as well as identify the most susceptible cell populations. We will also investigate if there is any difference in the distribution of the different types of cells in tissue using another new technique called "in situ sequencing". We will use this method to compare our results from the mouse model with tissue from Parkinson's patients. This study will provide highly valuable and important information that is useful for a broad section of the scientific community working with the nervous system.